Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19129823 | 1.00 | KEAP1 (0.59) | KEAP1NFE2L2 | |
| SCHEMBL19130207 | 0.93 | KEAP1 (0.55) | KEAP1NFE2L2 | |
| SCHEMBL19146576 | 0.89 | KEAP1 (0.56) | KEAP1NFE2L2 | |
| SCHEMBL24473720 | 0.88 | KEAP1 (0.60) | KEAP1NFE2L2 | |
| SCHEMBL24473722 | 0.88 | KEAP1 (0.54) | KEAP1NFE2L2 | |
| SCHEMBL19129847 | 0.88 | KEAP1 (0.54) | KEAP1NFE2L2 | |
| SCHEMBL24473698 | 0.87 | KEAP1 (0.54) | KEAP1NFE2L2 | |
| SCHEMBL19129822 | 0.85 | KEAP1 (0.55) | KEAP1NFE2L2 | |
| SCHEMBL13532040 | 0.85 | KEAP1 (0.55) | KEAP1NFE2L2 | |
| SCHEMBL30892082 | 0.85 | KEAP1 (0.55) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168253-A1 | PRODUCTION PROMOTER OF TYPE I COLLAGEN OR ELASTIN | DR'S CHOICE CO., LTD. (JP) | 2022-06-02 | — | — | US | disclosed |
| US-9522167-B2 | Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders | Nutratec, s.r.l. (IT) | 2016-12-20 | — | — | US | disclosed |
| US-9522167-B2 | Alphanizomenon flos aquae preparation, extracts and purified components thereof for the treatment of neurological, neurodegenerative and mood disorders | Nutratec, s.r.l. (IT) | 2016-12-20 | — | — | US | disclosed |
| US-8337858-B2 | Extracts of Aphanizomenon Flos Aquae and nutritional, cosmetic and pharmaceutical compositions containing the same | NUTRATEC S.R.L. (IT) | 2012-12-25 | — | — | US | disclosed |
| US-8337858-B2 | Extracts of Aphanizomenon Flos Aquae and nutritional, cosmetic and pharmaceutical compositions containing the same | NUTRATEC S.R.L. (IT) | 2012-12-25 | — | — | US | disclosed |
| US-20100021493-A1 | EXTRACTS OF APHANIZOMENON FLOS AQUAE AND NUTRITIONAL, COSMETIC AND PHARMACEUTICAL COMPOSITONS CONTAINING THE SAME | NUTRATEC S.R.L. (IT) | 2010-01-28 | — | — | US | disclosed |
| US-20100021493-A1 | EXTRACTS OF APHANIZOMENON FLOS AQUAE AND NUTRITIONAL, COSMETIC AND PHARMACEUTICAL COMPOSITONS CONTAINING THE SAME | NUTRATEC S.R.L. (IT) | 2010-01-28 | — | — | US | disclosed |
| US-20090311286-A1 | Alphanizomenon Flos Aquae Preparation, Extracts and Purified Components Thereof for the Treatment of Neurological, Neurodegenerative and Mood Disorders | NUTRATEC S.R.L. (IT) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311286-A1 | Alphanizomenon Flos Aquae Preparation, Extracts and Purified Components Thereof for the Treatment of Neurological, Neurodegenerative and Mood Disorders | TUBA1A, FECH, NDUFA6 | KEAP1 371/4885NFE2L2 1356/4885 |
| US-20220168253-A1 | PRODUCTION PROMOTER OF TYPE I COLLAGEN OR ELASTIN | COL14A1, COL2A1, COL1A1 | KEAP1 746/4885NFE2L2 2052/4885 |
| US-20100021493-A1 | EXTRACTS OF APHANIZOMENON FLOS AQUAE AND NUTRITIONAL, COSMETIC AND PHARMACEUTICAL COMPOSITONS CONTAINING THE SAME | CUTA, AAAS, FAH | KEAP1 658/4885NFE2L2 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.